Opinion|Videos|April 2, 2025
Recent Advancements in AD Treatment
Author(s)Matthew Zirwas, M.D.
An expert discusses the advancements in systemic and targeted therapies that have had the most significant impact on atopic dermatitis (AD) treatment in recent years as well as the cost-effectiveness and real-world outcomes of biologics and Janus kinase (JAK) inhibitors compared with traditional systemic therapies for AD
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your opinion, what advancements in systemic and targeted therapies have had the most significant impact on AD treatment in recent years?
- Based on your experience, how do the cost-effectiveness and real-world outcomes of biologics and JAK inhibitors compare with traditional systemic therapies for AD in your patient population?
Advertisement
Related to this article
Experts at Fall Clinical Derm 2026 urge early JAK inhibitors over systemic steroids for atopic dermatitis and long-term vitiligo treatment, saying boxed-warning risks are overstated.
Art Papier, M.D., CEO of VisualDx, says darker skin tones have been underrepresented in dermatology resources for decades and explains how his company works backward from known diagnostic errors.
The 2026 American Academy of Ophthalmology Meeting got started today in New Orleans with a mix of celebration and candor about the challenges facing ophthalmology today.
How LLM decision support reshapes dermatology care, helping non-specialists diagnose while navigating trust gaps, ambiguity, and hallucination risks at Fall Clinical Derm.
Real-world data at the 2026 Fall Clinical Dermatology Conference show dupilumab in children with atopic dermatitis cuts new allergies and asthma risk versus steroids.
Sagimet CEO David Happel shares insights on denifanstat, highlighting strong acne response, tolerability and optimism for a denifanstat U.S. trial.
Sagimet CEO David Happel says oral denifanstat could sharply cut antibiotic use in acne and be used before patients ever need isotretinoin.
Sagimet Biosciences’ denifanstat oral acne pill shows rapid, sustained lesion cuts and higher clear-skin rates in phase 3, offering an antibiotic-sparing option.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
A conversation about the cycle of ADHD and sleep problems in children, with Alison Pritchard, Ph.D.
2
PhRMA sues Trump administration over Medicare Part B drug pricing model
3
AI could utterly transform healthcare. But reduce its cost? Perhaps not so much.
4
Dupilumab linked to lower risk of new allergic conditions in children with atopic dermatitis | Fall Clinical Derm 2026
5